{"product_id":"bfly-vrio-analysis","title":"Butterfly Network, Inc. (BFLY): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Butterfly Network, Inc. (BFLY) truly equipped to dominate its market? This VRIO analysis cuts straight to the core, dissecting the firm's resources and capabilities based on their Value, Rarity, Inimitability, and Organization to determine if a sustainable competitive advantage exists. Dive into the findings below to see the distilled summary (\u0026amp;O4\u0026amp;) that reveals exactly where Butterfly Network, Inc. (BFLY) stands in the battle for market leadership.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eButterfly Network, Inc. (BFLY) - VRIO Analysis: Proprietary Ultrasound-on-Chip™ Semiconductor Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of Butterfly Network, Inc. (BFLY), and frankly, it’s the only reason the whole valuation story holds water right now. This Ultrasound-on-Chip™ technology is what lets them sell a whole-body imaging system with a single probe at a fraction of the cost of traditional cart-based machines. It’s a genuine attempt to democratize advanced imaging, which is a massive market opportunity, especially as they push toward their reaffirmed full-year 2025 revenue guidance of \u003cstrong\u003e$91 million to $95 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eValue: Foundation for Low-Cost, Whole-Body Imaging\u003c\/h\u003e\n\u003cp\u003eThe value proposition here is simple: miniaturization and cost reduction. By putting the ultrasound transducer onto a single semiconductor chip, they bypass the expensive, bulky, multi-element arrays that dominate the legacy space. This foundational tech enabled the Butterfly iQ3™, which earned the Best Medical Technology Award at the 2024 Prix Galien USA Awards - a huge validation point. This capability is key to their strategy, which saw Q3 2025 revenue hit \u003cstrong\u003e$21.5 million\u003c\/strong\u003e, growing \u003cstrong\u003e5%\u003c\/strong\u003e year-over-year, showing the market is responding to the value delivered.\u003c\/p\u003e\n\n\u003ch\u003eRarity: A Unique Semiconductor Integration\u003c\/h\u003e\n\u003cp\u003eHonestly, the specific integration of high-performance ultrasound onto a single, low-cost chip is still rare in the medical device field. While others are trying, Butterfly Network has been at this for years, building on their proprietary P4.3 semiconductor platform with the iQ3. They aren't just selling a new app; they are selling a fundamentally different way to build the hardware. This technological leap is what separates them from the pack relying on older, more complex transducer designs.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Protected by Patents and Know-How\u003c\/h\u003e\n\u003cp\u003eImitation is tough here, and that’s a good thing for you as an analyst. The core semiconductor process and the specific design architecture are locked down by patents and, just as important, deep engineering know-how that takes years to build. The company has a total of \u003cstrong\u003e450 patents\u003c\/strong\u003e, with recent filings detailing specific features like patterned membrane support layers in their transducer devices. That kind of intellectual property moat is hard to cross quickly, especially when competitors are still trying to match the performance of the P4.3 chip.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Effective Productization and Iteration\u003c\/h\u003e\n\u003cp\u003eThe organization seems to be effectively turning this tech into sellable products. Winning the Prix Galien for the iQ3 shows they can move from the lab to a recognized, market-ready device. They continue to iterate, which is crucial. Their cash position, ending Q3 2025 with \u003cstrong\u003e$144.2 million\u003c\/strong\u003e in cash and equivalents, gives them the runway to keep pushing these technological milestones, like the upcoming Compass AI software launch. They are organized to commercialize the chip’s potential.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Sustained Potential\u003c\/h\u003e\n\u003cp\u003eThe advantage here is currently \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e, but it’s conditional. It’s sustained only if they maintain the pace of innovation. If a competitor manages to leapfrog the P4.3 platform with a superior, manufacturable chip design, this advantage erodes fast. For now, the combination of their patented tech and award-winning product execution keeps them ahead of those using legacy, multi-element technology.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment for this core asset:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eScore (1=Low, 4=High)\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eEnables low-cost, portable, whole-body imaging.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Parity to Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eUnique, high-performance Ultrasound-on-Chip™ integration.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eProtected by \u003cstrong\u003e450\u003c\/strong\u003e patents and deep engineering knowledge.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eEffective productization (iQ3 Prix Galien win) and strong cash runway (\u003cstrong\u003e$144.2 million\u003c\/strong\u003e).\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the execution risk in scaling manufacturing to meet the full-year revenue target of \u003cstrong\u003e$91 million to $95 million\u003c\/strong\u003e while managing the cost of revenue, which saw a significant non-recurring charge in Q3 2025.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eButterfly Network, Inc. (BFLY) - VRIO Analysis: AI-Driven Software and Butterfly Garden Ecosystem\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eAI-Driven Software and Butterfly Garden Ecosystem\u003c\/h\u003e\u003c\/h\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Moves the offering from a hardware sale to a platform, enabling recurring revenue and expanding use cases via third-party apps like HeartFocus.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Butterfly Garden ecosystem includes partner apps such as HeartFocus, the first FDA-cleared Butterfly partner application, designed for simplified echocardiograms.\u003c\/li\u003e\n\u003cli\u003eEnterprise software subscription Annual Recurring Revenue (ARR) grew by \u003cstrong\u003e19%\u003c\/strong\u003e and now represents \u003cstrong\u003e46%\u003c\/strong\u003e of total ARR as of Q3 2024.\u003c\/li\u003e\n\u003cli\u003eSoftware and Other Services Revenue was \u003cstrong\u003e$7.0 million\u003c\/strong\u003e in Q3 2024, an increase of \u003cstrong\u003e5%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eFor Q3 2025, Software and Other Services Revenue remained at \u003cstrong\u003e$6.9 million\u003c\/strong\u003e, flat compared to the prior year period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Data\u003c\/td\u003e\n\u003ctd\u003eSource Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware and Other Services Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Revenue as % of Total\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e67.9%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate. Many medical device companies have software, but a dedicated, open ecosystem like the Butterfly Garden is less common for POCUS.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe launch of HeartFocus as the first FDA-cleared partner app in the Butterfly Garden ecosystem highlights a unique third-party integration strategy in POCUS.\u003c\/li\u003e\n\u003cli\u003eThe proprietary Ultrasound-on-Chip™ technology is cited as a key differentiator that reduces hardware cost and size.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Temporary. Competitors are rapidly building out their own software layers and partner programs.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company is developing the next-generation P5.1 chip, with a launch targeted for the second half of \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe AI lung tool demonstrated a \u003cstrong\u003e30%\u003c\/strong\u003e reduction in hospital length of stay in a POCUS CARE trial.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Improving. The launch of Compass AI before year-end 2025 shows they are organizing around the platform strategy.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompass AI, the next-generation enterprise software platform, was launched on November 17, \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCompass AI features an ambient voice dictation agent that cuts charting time by up to \u003cstrong\u003e25%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe platform is designed to enable documentation compliance rates of up to \u003cstrong\u003e94%\u003c\/strong\u003e, compared to traditional workflows capturing only about \u003cstrong\u003e15%\u003c\/strong\u003e of compliant studies.\u003c\/li\u003e\n\u003cli\u003eThe company reaffirmed 2025 revenue guidance of \u003cstrong\u003e$91 million to $95 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary. The first-mover advantage in building out a broad, integrated POCUS AI ecosystem is eroding.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company projects achieving cash flow breakeven by \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe projected annual revenue growth rate is \u003cstrong\u003e15.2%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe trailing 12-month use of cash was \u003cstrong\u003e$46 million\u003c\/strong\u003e as of the end of Q2 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eButterfly Network, Inc. (BFLY) - VRIO Analysis: Global Regulatory and Deployment Footprint\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Allows for revenue diversification across developed and emerging markets, as seen with the iQ3 launch across developed markets and significant deployments in Sub-Saharan Africa.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eButterfly iQ3 is commercially available in 16 European countries as of September 4, 2024, including Germany, France, and the UK.\u003c\/li\u003e\n\u003cli\u003eThe Gates Foundation-funded 1,000 Probe Partnership deployed 1,000 Butterfly iQ+ probes in Kenya and South Africa from September 2022 to December 2024.\u003c\/li\u003e\n\u003cli\u003eAs of July 2025, 1.8 million total scans have been conducted through this partnership, averaging 83,000 scans monthly.\u003c\/li\u003e\n\u003cli\u003eAn AI-powered gestational age calculator has been launched in Malawi and Uganda.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate. Many have global reach, but Butterfly’s specific success in resource-variable settings, evidenced by the SSA deployment, is a niche strength.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate. Regulatory hurdles create barriers, but established players can eventually navigate them. The Butterfly iQ+ system obtained its European Union Medical Device Regulation (EU MDR) certificate on March 20, 2024, allowing for the release of new features like Pulse Wave Doppler.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEU MDR became the governing framework for medical devices in Europe on May 26, 2021.\u003c\/li\u003e\n\u003cli\u003eThe newest device, Butterfly iQ3, is CE marked and certified under EU MDR.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High. They successfully operationalized the 1,000 Probe Partnership, training a significant number of workers and achieving high adoption rates in challenging environments.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eKenya Deployment (Phase 1)\u003c\/th\u003e\n\u003cth\u003eSouth Africa Deployment (Phase 2)\u003c\/th\u003e\n\u003cth\u003eTotal SSA Partnership (as of July 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProbes Deployed\u003c\/td\u003e\n\u003ctd\u003e500 iQ+ devices\u003c\/td\u003e\n\u003ctd\u003e500 iQ+ devices\u003c\/td\u003e\n\u003ctd\u003e1,000 probes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Workers Trained\u003c\/td\u003e\n\u003ctd\u003e514 workers\u003c\/td\u003e\n\u003ctd\u003e483 workers\u003c\/td\u003e\n\u003ctd\u003eOver 1,050 providers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacilities Supported\u003c\/td\u003e\n\u003ctd\u003e224 public facilities\u003c\/td\u003e\n\u003ctd\u003e467 facilities (cumulative)\u003c\/td\u003e\n\u003ctd\u003eOver 697 public health facilities\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Scans Conducted\u003c\/td\u003e\n\u003ctd\u003eOver 500,000 scans\u003c\/td\u003e\n\u003ctd\u003ePart of 1.8 million total\u003c\/td\u003e\n\u003ctd\u003e1.8 million scans\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial data relevant to global operations includes a $5.8 million grant from the Gates Foundation supporting the SSA deployment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. This is built on execution, which can be matched, but the real-world data gathered, such as the 20.6% decrease in maternal mortality in South Africa's Eastern Cape province in 12 months post-training, is hard to replicate quickly.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eButterfly Network, Inc. (BFLY) - VRIO Analysis: Next-Generation Chip Development Pipeline (P5.1 \u0026amp; Apollo)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eNext-Generation Chip Development Pipeline (P5.1 \u0026amp; Apollo)\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eValue\u003c\/strong\u003e: Ensures future performance parity or superiority.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eP5.1 chip is entering fab production.\u003c\/li\u003e\n\u003cli\u003eApollo AI chip is initiating development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003cstrong\u003eRarity\u003c\/strong\u003e: High.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSemiconductor technology has received an investment of over \u003cstrong\u003e$0.5 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eInvestment in cutting-edge semiconductor development continues.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003cstrong\u003eImitability\u003c\/strong\u003e: High.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRequires specialized semiconductor expertise and significant R\u0026amp;D investment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003cstrong\u003eOrganization\u003c\/strong\u003e: High.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents were \u003cstrong\u003e$144.2 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eFiscal Year 2025 revenue guidance is \u003cstrong\u003e$91 million to $95 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFiscal Year 2025 Adjusted EBITDA loss guidance is \u003cstrong\u003e$32 million - $35 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTargeting cash flow breakeven by \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eChip Generation\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eTarget Performance Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eP5.1 (Fourth-Generation)\u003c\/td\u003e\n\u003ctd\u003eEntering fab production; expected debut in second half of next year.\u003c\/td\u003e\n\u003ctd\u003eIncreased mechanical impedance over prior generations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApollo AI (Fifth-Generation)\u003c\/td\u003e\n\u003ctd\u003eInitiating development.\u003c\/td\u003e\n\u003ctd\u003eIntended to produce \u003cstrong\u003e10 times\u003c\/strong\u003e the processing power of iQ3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eButterfly Network, Inc. (BFLY) - VRIO Analysis: Enterprise Workflow Integration and Software Readiness\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Addresses the needs of large hospital systems by improving documentation compliance and program management, which is key for scaling U.S. enterprise sales.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While all enterprise software aims for this, Butterfly’s specific integration with their handheld device is unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary. Competitors are focused on similar enterprise readiness, especially with new software like Compass AI.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The launch of Compass AI in late 2025 directly targets this organizational focus.\u003c\/p\u003e\n\u003cp\u003eThe organizational focus is supported by recent financial traction, such as \u003cstrong\u003eQ2 2025\u003c\/strong\u003e revenue of \u003cstrong\u003e$23.383M\u003c\/strong\u003e and a gross margin of \u003cstrong\u003e63.7%\u003c\/strong\u003e in that quarter. The company also raised its \u003cstrong\u003eFY25\u003c\/strong\u003e revenue guidance to \u003cstrong\u003e$91–$95M\u003c\/strong\u003e as of August 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eTraditional Workflow\u003c\/td\u003e\n\u003ctd\u003eCompass AI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDocumentation Compliance Rate\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e15%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e94%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnbilled Exams (Potential)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e85%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReduced significantly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Potential (Same Volume)\u003c\/td\u003e\n\u003ctd\u003eBaseline\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003efive times\u003c\/strong\u003e more\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a necessary feature for growth, not a unique differentiator long-term.\u003c\/p\u003e\n\u003cp\u003eKey features of Compass AI, launched in November 2025, that drive this value proposition include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDocumentation Agent: Cuts charting time by up to \u003cstrong\u003e25%\u003c\/strong\u003e via ambient voice dictation.\u003c\/li\u003e\n\u003cli\u003eProgram Dashboard: Tracks usage, compliance, credentialing, and unbilled scans.\u003c\/li\u003e\n\u003cli\u003eIntegration: Connects with EHRs, PACS, and SSO.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eButterfly Network, Inc. (BFLY) - VRIO Analysis: Clinical Validation and External Recognition\n\u003c\/h2\u003e\n\u003cp\u003e\nThe following data quantifies the VRIO framework components related to Butterfly Network's Clinical Validation and External Recognition.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment Level\u003c\/th\u003e\n\u003cth\u003eSupporting Real-Life Data\/Metrics\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$751,537\u003c\/strong\u003e in direct cost savings demonstrated in a single Quality Improvement (QI) evaluation published in \u003cem\u003eJAMA\u003c\/em\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eHigh-impact validation showing clear cost\/outcome benefits is rarer than general device publications.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eBuilt over years of academic collaboration, including a trial with Rutgers Robert Wood Johnson Medical School, and successful trial execution.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eInclusion in TIME’s World's Top HealthTech Companies \u003cstrong\u003e2025\u003c\/strong\u003e and winning Dual Category Awards at the \u003cstrong\u003e2025\u003c\/strong\u003e Medical Device Network Excellence Awards.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\nDe-risks adoption for large buyers by providing peer-reviewed evidence.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nJAMA study trial showed \u003cstrong\u003e$751,537\u003c\/strong\u003e in direct cost savings in admissions for undifferentiated dyspnea.\n\u003c\/li\u003e\n\u003cli\u003e\nThe same study demonstrated a \u003cstrong\u003e30%\u003c\/strong\u003e reduction in expected hospital length of stay (\u003cstrong\u003e8.3\u003c\/strong\u003e days vs. \u003cstrong\u003e11.9\u003c\/strong\u003e days).\n\u003c\/li\u003e\n\u003cli\u003e\nThe incremental cost-effectiveness ratio was \u003cstrong\u003e$3,055\u003c\/strong\u003e per hospital bed day saved.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\nMany devices receive publication, but high-impact validation showing clear cost\/outcome benefits is rarer.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe POCUS-CARE trial reached \u003cstrong\u003e208\u003c\/strong\u003e patients across a six-month stepped-wedge QI evaluation.\n\u003c\/li\u003e\n\u003cli\u003e\nClinical impact: POCUS changed clinical management in \u003cstrong\u003e35%\u003c\/strong\u003e of cases in the published study.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\nThis is built over years of academic collaboration and successful trial execution.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe core validation involved a collaborative model with hospitalists, sonographer mentoring, and remote cardiologist support.\n\u003c\/li\u003e\n\u003cli\u003e\nThe Butterfly iQ3, the latest device, followed the iQ+ (\u003cstrong\u003e2020\u003c\/strong\u003e) and the original Butterfly iQ (\u003cstrong\u003e2018\u003c\/strong\u003e) launch.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\nBeing named to TIME’s Top HealthTech Companies \u003cstrong\u003e2025\u003c\/strong\u003e and winning \u003cstrong\u003e2025\u003c\/strong\u003e Medical Device Network Excellence Awards boosts credibility.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe TIME ranking recognized \u003cstrong\u003e400\u003c\/strong\u003e companies out of thousands reviewed, based on Financial Performance Metrics (\u003cstrong\u003e50%\u003c\/strong\u003e of score), Reputation Analysis (\u003cstrong\u003e30%\u003c\/strong\u003e), and Online Engagement (\u003cstrong\u003e20%\u003c\/strong\u003e).\n\u003c\/li\u003e\n\u003cli\u003e\nButterfly Network won the Medical Device Network Excellence Award for Innovation in the AI: Imaging category and Business Expansion in the Imaging Platforms category in \u003cstrong\u003e2025\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\nSustained. A strong, growing body of peer-reviewed evidence acts as a powerful barrier to entry for new entrants.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nClinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software can improve care workflows.\n\u003c\/li\u003e\n\u003cli\u003e\nThe iQ3 device leverages proprietary P4.3 semiconductor technology, representing an evolution from prior generations.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eButterfly Network, Inc. (BFLY) - VRIO Analysis: Strategic Non-Medical Licensing Revenue Stream\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nCreates a high-margin, non-dilutive revenue stream independent of core medical sales cycles, evidenced by the Midjourney deal structure. The deal includes a $15 million one-time fee and $10 million in annual license fees.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh. Licensing core medical imaging IP to a major generative AI lab like Midjourney is unprecedented.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh. This required a unique strategic vision and a specific, high-value technology platform (ultrasound-on-chip).\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh. The deal structure shows management successfully monetized this IP through a dedicated subsidiary, Octiv™, formed to capitalize on non-medical sectors.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Component\u003c\/td\u003e\n\u003ctd\u003eAmount\/Term\u003c\/td\u003e\n\u003ctd\u003eNotes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Fee\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOne-time non-recurring fee.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual License Fee\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePayable quarterly over the five-year term.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Milestone Payments\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eContingent on specified milestones.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimum 5-Year Contract Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$65 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$15M upfront + (5 years  $10M annual fee).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. This specific deal is unique, but the ability to strike such deals could become a repeatable asset if they secure more partners under the 'Powered by Butterfly™ chip licensing program.'\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eButterfly Network, Inc. (BFLY) - VRIO Analysis: Improved Unit Economics and Gross Margin Performance\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nDemonstrates a clear path to profitability at scale, with Adjusted Gross Margin reaching \u003cstrong\u003e63.9%\u003c\/strong\u003e in Q3 2025, up from \u003cstrong\u003e60.0%\u003c\/strong\u003e the prior year.\n\u003c\/p\u003e\n\u003cp\u003e\nThe Adjusted Gross Profit for the three months ended September 30, 2025, was \u003cstrong\u003e$13.7 million\u003c\/strong\u003e versus \u003cstrong\u003e$12.3 million\u003c\/strong\u003e in the prior year period. The adoption of the iQ3 probe exceeded expectations, driving approximately \u003cstrong\u003e85%\u003c\/strong\u003e of probe volume in Q3, supporting pricing and margin improvements. The GAAP Gross Margin for Q3 2025 was negative \u003cstrong\u003e17.5%\u003c\/strong\u003e, impacted by a \u003cstrong\u003e$17.4 million\u003c\/strong\u003e non-cash inventory write-off.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Value\u003c\/th\u003e\n\u003cth\u003ePrior Year Q3 Value\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Gross Profit (in thousands)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13,700\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12,300\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-17.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e59.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eiQ3 Probe Volume Mix\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\approx 85\\%$\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate. Many hardware companies struggle to maintain high margins while driving down unit cost.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate. Competitors can improve their own margins, but Butterfly’s is tied to their unique chip structure.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh. Management is clearly focused on this, as evidenced by the improved margin despite macro headwinds.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFull-year 2025 revenue guidance was reaffirmed at \u003cstrong\u003e$91 million\u003c\/strong\u003e to \u003cstrong\u003e$95 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull-year 2025 Adjusted EBITDA loss guidance was tightened to a loss range of \u003cstrong\u003e$(32) million\u003c\/strong\u003e - \u003cstrong\u003e$(35) million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQuarterly cash burn was reduced to a record low of \u003cstrong\u003e$3.9 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of September 30, 2025, were \u003cstrong\u003e$144.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. Margin expansion is expected as they scale; it proves the model works, but it’s not a permanent advantage.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eButterfly Network, Inc. (BFLY) - VRIO Analysis: Liquidity and Cash Management Discipline\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Provides a necessary buffer to fund R\u0026amp;D and navigate long sales cycles, with cash and equivalents at \u003cstrong\u003e$144.2 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Low. Having cash is common, but reducing quarterly cash burn to a record low of \u003cstrong\u003e$3.9 million\u003c\/strong\u003e in Q3 2025 is a sign of operational control.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low. This is a function of financial management and cost control, which any company can implement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High. The company is clearly organized to manage its burn rate effectively to meet its revised \u003cstrong\u003e$91 million\u003c\/strong\u003e–\u003cstrong\u003e$95 million\u003c\/strong\u003e 2025 revenue guidance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. This is a financial hygiene factor; it buys time but doesn't create market share on its own.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\u003cp\u003eThe cash position as of September 30, 2025, of \u003cstrong\u003e$144.2 million\u003c\/strong\u003e reflects a significant increase from the \u003cstrong\u003e$88.8 million\u003c\/strong\u003e reported at the end of 2024. This liquidity supports operations while the company manages its path to profitability.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.56 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuarterly Cash Burn (Normalized)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A (Record Low in Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(8.1 million)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(8.45) million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(6.2 million)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (End of Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$144.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$152 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational discipline is evidenced by the sequential reduction in cash usage and the achievement of key financial milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQuarterly cash burn reduced to a record low of \u003cstrong\u003e$3.9 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eTrailing 12-month use of cash was \u003cstrong\u003e$31.5 million\u003c\/strong\u003e as of Q3 2025.\u003c\/li\u003e\n\u003cli\u003eAdjusted Gross Margin improved to \u003cstrong\u003e63.9%\u003c\/strong\u003e in Q3 2025, up from \u003cstrong\u003e60.0%\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eAdjusted EPS for Q3 2025 was \u003cstrong\u003e$(0.04)\u003c\/strong\u003e, an improvement from \u003cstrong\u003e$(0.05)\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eFull-year 2025 revenue guidance reaffirmed at \u003cstrong\u003e$91 million\u003c\/strong\u003e to \u003cstrong\u003e$95 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company's organization is focused on capital efficiency to support its strategic roadmap, including:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdvancing AI development, such as the launch of Compass AI before year-end.\u003c\/li\u003e\n\u003cli\u003eCompletion of P5.1 chip development and initiation of sixth-generation Apollo AI chip development.\u003c\/li\u003e\n\u003cli\u003eAchieving ISO 27001 certification and additional international security accreditations.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516123439253,"sku":"bfly-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/bfly-vrio-analysis.png?v=1740156018","url":"https:\/\/dcf-model.com\/products\/bfly-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}